Toronto Dominion Bank
ZYNE

Toronto Dominion Bank’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Toronto Dominion Bank’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,056
Closed -$1K – 1631
2022
Q3 		$1K Buy
1,056
+653
+162% +$741 ﹤0.01% 1540
2022
Q2 		$0 Hold
403
– – ﹤0.01% 2029
2022
Q1 		$1K Sell
403
-561
-58% -$1.33K ﹤0.01% 1362
2021
Q4 		$3K Buy
964
+664
+221% +$2.46K ﹤0.01% 1432
2021
Q3 		$1K Buy
+300
New +$1.34K ﹤0.01% 1361
2021
Q1 		– Sell
-192
Closed -$1K – 1612
2020
Q4 		$1K Buy
192
+15
+8% +$57 ﹤0.01% 1334
2020
Q3 		$1K Sell
177
-132
-43% -$485 ﹤0.01% 1212
2020
Q2 		$1K Sell
309
-85
-22% -$402 ﹤0.01% 1218
2020
Q1 		$2K Buy
+394
New +$1.83K ﹤0.01% 1175
2019
Q4 		– Sell
-701
Closed -$5K – 1593
2019
Q3 		$5K Buy
701
+607
+646% +$6.84K ﹤0.01% 1338
2019
Q2 		$1K Buy
94
+57
+154% +$658 ﹤0.01% 1423
2019
Q1 		$0 Sell
37
-130
-78% -$633 ﹤0.01% 1786
2018
Q4 		$0 Buy
+167
New +$914 ﹤0.01% 1701
2017
Q4 		– Sell
-199
Closed -$2K – 1324
2017
Q3 		$2K Buy
+199
New +$2.1K ﹤0.01% 1120

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

Toronto Dominion Bank's ZYNE Position: Q4 2022 in Review

Toronto Dominion Bank sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2022, closing a stake of 1,056 shares — an estimated $1K sold.

Toronto Dominion Bank first reported a position in ZYNE in Q3 2017 and held it in 14 quarters. The position peaked at $5K in Q3 2019. 50 funds tracked by Wall St. Rank hold ZYNE as of Q4 2022.

  • Toronto Dominion Bank reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2022 after selling out during the quarter.
  • Toronto Dominion Bank sold 1,056 Zynerba Pharmaceuticals, Inc shares in Q4 2022, an estimated $1K.
  • Toronto Dominion Bank first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2017 and held it in 14 quarters.
  • Toronto Dominion Bank's Zynerba Pharmaceuticals, Inc position peaked at $5K in Q3 2019.
  • 50 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2022.

Based on Toronto Dominion Bank's 13F filing for Q4 2022, filed 7 Feb 2023.